CoChat
Sign Up
Cited by 114

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effects of proton pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials

Wang, Wei Hong, Huang, Jia Qing, Zheng, Ge Fan, Xia, Harry H.X., Wong, Wai Man, Liu, Xin Guang, Karlberg, Johan, Wong, Benjamin C.Y.·2007·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2006.09.012
Open this paper in CoChat — free account

Abstract

Background & aims The aim of this study was to assess systematically the efficacy of proton pump inhibitors (PPIs) in the treatment of functional dyspepsia compared with placebo and to determine if any difference in the response exists between symptom subgroups of functional dyspepsia. Methods A literature search was performed through September 2005 in PubMed, Medline, Embase, CINAHL, and Cochrane databases to include randomized, double-blind, placebo-controlled trials evaluating the efficacy of PPIs for the treatment of functional dyspepsia. Relative risk (RR) and relative risk reduction (RRR) and 95% confidence intervals (CI) were calculated under a random-effects model. Results Seven studies with a total of 3725 patients were identified. PPIs were found to be more effective than placebo for reducing symptoms in patients with functional dyspepsia (RRR, 10.3%; 95% CI, 2.7%-17.3%). The estimated number needed to treat is 14.6 (95% CI, 8.7-57.1). When stratified analyses were performed, a significant difference in the efficacy was observed only in patients with ulcer-like (RRR, 12.8%; 95% CI, 7.2%-18.1%) and reflux-like dyspepsia (RRR, 19.7%; 95% CI, 1.8%-34.3%), but not in those with dysmotility-like (RRR, 5.1%; 95% CI, -10.9% to 18.7%) and unspecified dyspepsia (RRR, -8.0%; 95% CI, -23.7% to 5.6%). The effect of H pylori on the efficacy of PPIs remains unclear. Significant heterogeneity among studies was found for the overall analysis, dysmotility-like dyspepsia, H pylori-ne…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2006.09.012

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The effect of PPIs compared with placebo on functional dyspepsia does not differ by country of origin.

    “Although this was suggested by Wang 2007 as a potential source of heterogeneity, this was not the case in our Cochrane Database of Systematic Reviews analysis as we found no differences between subgroups.”

    From Proton pump inhibitors for functional dyspepsia (2017) · cites this paper as Wang 2007

  • The results from this review were similar to the findings of previous systematic reviews (Moayyedi 2006; Wang 2007), supporting the beneficial effect of PPIs in functional dyspepsia.

    “The fact that the results from our review were similar to the findings of previous systematic reviews (Moayyedi 2006; Wang 2007) support the beneficial effect of PPIs in FD”

    From Proton pump inhibitors for functional dyspepsia (2017) · cites this paper as Wang 2007

  • There is a discrepancy with the review's findings on dyspepsia subtype compared to Wang 2007, which could be related to the inclusion of studies with different definitions of functional dyspepsia.

    “There is a discrepancy with our findings on the dyspepsia subtype compared to the analysis from Wang 2007, and this could be related to the inclusion of studies with different definitions of FD.”

    From Proton pump inhibitors for functional dyspepsia (2017) · cites this paper as Wang 2007

  • The definition of functional dyspepsia using Rome III criteria is stricter than previous definitions of functional dyspepsia in excluding participants with reflux symptoms.

    “the definition of FD using the Rome III criteria is stricter than previous definitions of FD in excluding participants with reflux symptoms.”

    From Proton pump inhibitors for functional dyspepsia (2017) · cites this paper as Wang 2007

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 57

  1. Talley, 1999, Functional gastroduodenal disorders, Gut, 45, ii37
  2. Moayyedi, 2002, Clinical and economic consequences of dyspepsia in the community, Gut, 50, iv10
  3. Talley, 1995, Impact of functional dyspepsia on quality of life, Dig Dis Sci, 40, 584, 10.1007/BF02064375 · DOI
  4. Talley, 1998, Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies), Aliment Pharmacol Ther, 12, 1055, 10.1046/j.1365-2036.1998.00410.x · DOI
  5. Bolling-Sternevald, 2002, Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial, Scand J Gastroenterol, 37, 1395, 10.1080/003655202762671260 · DOI
  6. Blum, 2000, Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status, Gut, 47, 473, 10.1136/gut.47.4.473 · DOI
  7. Finney, 1998, Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia, J Clin Gastroenterol, 26, 312, 10.1097/00004836-199806000-00022 · DOI
  8. Allescher, 2001, Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies, Scand J Gastroenterol, 36, 934, 10.1080/003655201750305440 · DOI
  9. Soo, 2000, Pharmacological interventions for non-ulcer dyspepsia, Cochrane Database Syst Rev, 2
  10. Wong, 2002, Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients, Gut, 51, 502, 10.1136/gut.51.4.502 · DOI
  11. Talley, 1992, Dyspepsia and dyspepsia subgroups: a population-based study, Gastroenterology, 102, 1259, 10.1016/0016-5085(92)90764-P · DOI
  12. Grainger, 1994, Prevalence of dyspepsia: the epidemiology of overlapping symptoms, Postgrad Med J, 70, 154, 10.1136/pgmj.70.821.154 · DOI
  13. Moayyedi, 2003, Pharmacological interventions for non-ulcer dyspepsia, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD001960 · DOI
  14. Moayyedi, 2004, The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis, Gastroenterology, 127, 1329, 10.1053/j.gastro.2004.08.026 · DOI
  15. Farup, 1999, Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern, Scand J Gastroenterol, 34, 575, 10.1080/003655299750026029 · DOI
  16. Gerson, 2005, A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia, Dig Liver Dis, 37, 87, 10.1016/j.dld.2004.09.021 · DOI
  17. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  18. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  19. Peura, 2004, Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials, Am J Med, 116, 740, 10.1016/j.amjmed.2004.01.008 · DOI
  20. Hengels, 1998, Therapeutic efficacy of 15 mg lansoprazole mane in 269 patients suffering from non-ulcer dyspepsia (NUD): a multicentre, randomized, double-blind study, Gut, 43, A89
  21. Laheij, 1998, Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis, Aliment Pharmacol Ther, 12, 1249, 10.1046/j.1365-2036.1998.00423.x · DOI
  22. Lewin-van-den-Broek, 2001, A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome, Br J Gen Pract, 51, 619
  23. Meineche-Schmidt, 2000, Which dyspepsia patients will benefit from omeprazole treatment?, Am J Gastroenterol, 95, 2777
  24. Rabeneck, 2002, A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia, Am J Gastroenterol, 97, 3045, 10.1111/j.1572-0241.2002.07123.x · DOI
  25. Meineche-Schmidt, 2001, The symptom relieving effect of omeprazole 40 mg daily is not significantly better than 20 mg in patients with acid related disease from general practice, Gastroenterology, 120, A730, 10.1016/S0016-5085(08)83637-2 · DOI
  26. Meineche-Schmidt, 2004, Classification of dyspepsia and response to treatment with proton-pump inhibitors, Aliment Pharmacol Ther, 20, 1171, 10.1111/j.1365-2036.2004.02243.x · DOI
  27. Meineche-Schmidt, 2004, Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption, Am J Gastroenterol, 99, 1050, 10.1111/j.1572-0241.2004.30089.x · DOI
  28. Veldhuyzen van Zanten, 2005, A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study, Am J Gastroenterol, 100, 1477, 10.1111/j.1572-0241.2005.40280.x · DOI
  29. Bytzer, 2000, Identifying responders to acid suppression in dyspepsia using a random starting day trial, Aliment Pharmacol Ther, 14, 1485, 10.1046/j.1365-2036.2000.00866.x · DOI
  30. Goves, 1998, First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice, Aliment Pharmacol Ther, 12, 147, 10.1046/j.1365-2036.1998.0284f.x · DOI
  31. Jones, 1999, Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia, Aliment Pharmacol Ther, 13, 413, 10.1046/j.1365-2036.1999.00455.x · DOI
  32. Jones, 1997, Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice, Aliment Pharmacol Ther, 11, 541, 10.1046/j.1365-2036.1997.00179.x · DOI
  33. Mason, 1998, The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy, Aliment Pharmacol Ther, 12, 263, 10.1046/j.1365-2036.1998.00282.x · DOI
  34. Madsen, 2004, Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design, Aliment Pharmacol Ther, 20, 365, 10.1111/j.1365-2036.2004.02072.x · DOI
  35. Madsen, 2004, Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial—is gastro-oesophageal reflux important?, Aliment Pharmacol Ther, 20, 423, 10.1111/j.1365-2036.2004.02084.x · DOI
  36. Meineche-Schmidt, 1999, Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment, Scand J Gastroenterol, 34, 566, 10.1080/003655299750026010 · DOI
  37. Singh, 2001, Which patients with ulcer- or reflux-like dyspepsia will respond favorably to omeprazole?, J Fam Pract, 50, 365
  38. Talley, 2002, The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies, Gut, 50, iv36
  39. Lauritsen, 1996, Effect of omeprazole in functional dyspepsia: a double-blind, randomized, placebo-controlled study, Gastroenterology, 110, A702
  40. Peura, 2000, Low-dose lansoprazole: effective for non-ulcer dyspepsia (NUD), Gastroenterology, 118, A439, 10.1016/S0016-5085(00)83870-6 · DOI
  41. Pilmer, 2001, Low-dose lansoprazole: effective for non-ulcer dyspepsia (NUD), Gut, 49, A1873
  42. Bolling-Sternevald, 2003, Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?, Aliment Pharmacol Ther, 18, 117, 10.1046/j.1365-2036.2003.01651.x · DOI
  43. Goh, 2000, Gastro-oesophageal reflux disease in Asia, J Gastroenterol Hapatol, 15, 230, 10.1046/j.1440-1746.2000.02148.x · DOI
  44. Quigley, 2001, Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both?, Eur J Gastroenterol Hepatol, 13, S13
  45. Mantinez, 2003, Non-erosive reflux disease (NERD)—acid reflux and symptom patterns, Aliment Pharmacol Ther, 17, 537, 10.1046/j.1365-2036.2003.01423.x · DOI
  46. Richter, 2000, Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease, Arch Intern Med, 160, 1803, 10.1001/archinte.160.12.1803 · DOI
  47. van, 2001, Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease, Cochrane Database Syst Rev, 4
  48. Armstrong, 2001, Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease, Am J Gastroenterol, 96, 2849
  49. Small, 1995, Importance of reflux symptoms in functional dyspepsia, Gut, 36, 189, 10.1136/gut.36.2.189 · DOI
  50. Laine, 2001, Therapy for Helicobacter pylori in patients with nonulcer dyspepsia, Ann Intern Med, 134, 361, 10.7326/0003-4819-134-5-200103060-00008 · DOI
  51. Moayyedi, 2001, Eradication of Helicobacter pylori for non-ulcer dyspepsia, Cochrane Database Syst Rev, 1
  52. Abraham, 2004, Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia, Aliment Pharmacol Ther, 19, 631, 10.1111/j.1365-2036.2004.01878.x · DOI
  53. El-Omar, 1995, A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients, Gut, 36, 534, 10.1136/gut.36.4.534 · DOI
  54. Treiber, 2004, Dyspeptic symptoms associated with Helicobacter pylori infection are influenced by strain and host specific factors, Aliment Pharmacol Ther, 19, 219, 10.1111/j.1365-2036.2004.01751.x · DOI
  55. Davey Smith, 1998, Meta-analysis: unresolved issues and future developments, BMJ, 316, 221, 10.1136/bmj.316.7126.221 · DOI · Paper page
  56. Veldhuyzen van Zanten, 1996, Drug treatment of functional dyspepsia: a systematic analysis of trials methodology with recommendations for design of future trials, Am J Gastroenterol, 91, 660
  57. Westbrook, 2000, The impact of dyspepsia definition on prevalence estimates: considerations for future researchers, Scand J Gastroenterol, 35, 227, 10.1080/003655200750024065 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, W. H., Huang, J. Q., Zheng, G. F., Xia, H. H. X., Wong, W. M., Liu, X. G., Karlberg, J., & Wong, B. C. Y.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2007-02
Volume
5
Issue
2
Pages
178-185
ISSN
1542-3565
DOI
10.1016/j.cgh.2006.09.012
Cited by
114
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review